Canadian society of clinical chemists (CSCC) interim consensus guidance for testing and reporting of SARS-CoV-2 serology Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • Clinical laboratories across the world are working to validate and perform testing for SARS-CoV-2 antibodies. Herein, we present interim consensus guidance for Canadian clinical laboratories testing and reporting SARS-CoV-2 serology, with emphasis on the capabilities and limitations of these tests and recommendations for interpretative comments in an effort to achieve harmonized laboratory practices. The consensus document provides a broad overview of topics including sample type and contamination risk; kinetics of antibody response to COVID-19 and the impact on serology testing; clinical utility of SARS-CoV-2 serology testing; clinical performance of commercial laboratory-based assays commonly deployed in North America; recommendations for interim reporting; utility of SARS-CoV-2 antibody testing for pediatric patients; and utility of point-of-care testing. The information is based on the current literature and is subject to change as additional information becomes available.

authors

  • Bailey, Dana
  • Konforte, Danijela
  • Barakauskas, Vilte E
  • Yip, Paul M
  • Kulasingam, Vathany
  • Abou El Hassan, Mohamed
  • Beach, Lori A
  • Blasutig, Ivan M
  • Catomeris, Peter
  • Dooley, Kent C
  • Gong, Yanping
  • Kavsak, Peter
  • Randell, Edward W
  • Robinson, Jason L
  • Shaw, Julie
  • Taher, Jennifer
  • White-Al Habeeb, Nicole

publication date

  • December 2020